(Q41148040)

English

First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults

scientific article published on 19 June 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

27 September 2017

First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults (English)

1 reference

Europe PubMed Central

27 September 2017

Mycobacterium tuberculosis

0 references

1 reference

based on heuristic

inferred from title

8

object named as

Mark Hatherill

1 reference

Europe PubMed Central

27 September 2017

Willem Albert Hanekom

10

object named as

Willem A Hanekom

1 reference

Europe PubMed Central

27 September 2017

Thomas J Scriba

12

object named as

Thomas J Scriba

1 reference

Europe PubMed Central

27 September 2017

Gregory D Hussey

26

object named as

Gregory D Hussey

1 reference

Europe PubMed Central

27 September 2017

author name string

Angelique Kany Kany Luabeya

1

1 reference

Europe PubMed Central

27 September 2017

Benjamin M N Kagina

2

1 reference

Europe PubMed Central

27 September 2017

Michele D Tameris

3

1 reference

Europe PubMed Central

27 September 2017

Hennie Geldenhuys

4

1 reference

Europe PubMed Central

27 September 2017

Soren T Hoff

5

1 reference

Europe PubMed Central

27 September 2017

Zhongkai Shi

6

1 reference

Europe PubMed Central

27 September 2017

Ingrid Kromann

7

1 reference

Europe PubMed Central

27 September 2017

Hassan Mahomed

9

1 reference

Europe PubMed Central

27 September 2017

Peter Andersen

11

1 reference

Europe PubMed Central

27 September 2017

H56-032 Trial Study Group

13

1 reference

Europe PubMed Central

27 September 2017

Elisma Schoeman

14

1 reference

Europe PubMed Central

27 September 2017

Colleen Krohn

15

1 reference

Europe PubMed Central

27 September 2017

Cheryl L Day

16

1 reference

Europe PubMed Central

27 September 2017

Hadn Africa

17

1 reference

Europe PubMed Central

27 September 2017

Lebohang Makhethe

18

1 reference

Europe PubMed Central

27 September 2017

Erica Smit

19

1 reference

Europe PubMed Central

27 September 2017

Yolande Brown

20

1 reference

Europe PubMed Central

27 September 2017

Sara Suliman

21

1 reference

Europe PubMed Central

27 September 2017

E Jane Hughes

22

1 reference

Europe PubMed Central

27 September 2017

Peter Bang

23

1 reference

Europe PubMed Central

27 September 2017

Margaret A Snowden

24

1 reference

Europe PubMed Central

27 September 2017

Bruce McClain

25

1 reference

Europe PubMed Central

27 September 2017

language of work or name

0 references

publication date

19 June 2015

1 reference

Europe PubMed Central

27 September 2017

number of pages

11

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

27 September 2017

33

1 reference

Europe PubMed Central

27 September 2017

33

1 reference

Europe PubMed Central

27 September 2017

4130-4140

1 reference

Europe PubMed Central

27 September 2017

Prospects for Tuberculosis Elimination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

A multistage tuberculosis vaccine that confers efficient protection before and after exposure.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

Protective immunity to tuberculosis with Ag85B-ESAT-6 in a synthetic cationic adjuvant system IC31.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

Linking the transcriptional profiles and the physiological states of Mycobacterium tuberculosis during an extended intracellular infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

An increase in expression of a Mycobacterium tuberculosis mycolyl transferase gene (fbpB) occurs early after infection of human monocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

Crystal structure of the secreted form of antigen 85C reveals potential targets for mycobacterial drugs and vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

Mycobacterium tuberculosis secretory proteins CFP-10, ESAT-6 and the CFP10:ESAT6 complex inhibit lipopolysaccharide-induced NF-kappaB transactivation by downregulation of reactive oxidative species (ROS) production

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

The multistage vaccine H56 boosts the effects of BCG to protect cynomolgus macaques against active tuberculosis and reactivation of latent Mycobacterium tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

Impact of in vitro evolution on antigenic diversity of Mycobacterium bovis bacillus Calmette-Guerin (BCG)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

Comparative genomics of BCG vaccines by whole-genome DNA microarray

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

Immunomodulatory action of mycobacterial secretory proteins.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

Identification and HLA restriction of naturally derived Th1-cell epitopes from the secreted Mycobacterium tuberculosis antigen 85B recognized by antigen-specific human CD4(+) T-cell lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

Multiple epitopes from the Mycobacterium tuberculosis ESAT-6 antigen are recognized by antigen-specific human T cell lines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

Evaluation of a nutrient starvation model of Mycobacterium tuberculosis persistence by gene and protein expression profiling

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

Higher human CD4 T cell response to novel Mycobacterium tuberculosis latency associated antigens Rv2660 and Rv2659 in latent infection compared with tuberculosis disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

A comprehensive proteomic analysis of Mycobacterium bovis bacillus Calmette-Guérin using high resolution Fourier transform mass spectrometry

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

A small RNA encoded in the Rv2660c locus of Mycobacterium tuberculosis is induced during starvation and infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

Mycobacterium tuberculosis gene expression during adaptation to stationary phase and low-oxygen dormancy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

Control of chronic mycobacterium tuberculosis infection by CD4 KLRG1- IL-2-secreting central memory cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

The who's who of T-cell differentiation: human memory T-cell subsets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

Ag85B-ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

Primary immunization of premature infants with gestational age <35 weeks: cardiorespiratory complications and C-reactive protein responses associated with administration of single and multiple separate vaccines simultaneously

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

Mycobacterium tuberculosis dormancy-associated antigen of Rv2660c induces stronger immune response in latent Mycobacterium tuberculosis infection than that in active tuberculosis in a Chinese population

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

Bioinformatic and empirical analysis of novel hypoxia-inducible targets of the human antituberculosis T cell response

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

Protection against Mycobacterium tuberculosis infection offered by a new multistage subunit vaccine correlates with increased number of IFN-γ+ IL-2+ CD4+ and IFN-γ+ CD8+ T cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

Induction and regulation of T-cell immunity by the novel tuberculosis vaccine M72/AS01 in South African adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

Phenotype and function of human T lymphocyte subsets: consensus and issues

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

Functional and phenotypic characterization of tetanus toxoid-specific human CD4+ T cells following re-immunization.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

Protection and polyfunctional T cells induced by Ag85B-TB10.4/IC31 against Mycobacterium tuberculosis is highly dependent on the antigen dose

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

Longitudinal changes in CD4(+) T-cell memory responses induced by BCG vaccination of newborns

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

Bacillus Calmette-Guérin vaccination of human newborns induces T cells with complex cytokine and phenotypic profiles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

Central memory and effector memory T cell subsets: function, generation, and maintenance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.06.051

7 January 2021

Identifiers

10.1016/J.VACCINE.2015.06.051

1 reference

Europe PubMed Central

27 September 2017

release_zy3u43oo5ze47g7ufuv7a4xcca

1 reference

https://api.fatcat.wiki/v0/release/zy3u43oo5ze47g7ufuv7a4xcca

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

27 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41148040&oldid=1915996524"